Mpox drug TPOXX put to the test in 328-Patient trial

NCT ID NCT06721585

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed trial tested the antiviral drug tecovirimat (TPOXX) in 328 adults and children with mpox. Participants received either tecovirimat or a placebo to see if the drug speeds up healing of skin lesions. The study also tracked safety and natural disease progression during the outbreak.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tecovirimat (TPOXX) oral capsules
What this could lead to: If effective, tecovirimat could become a standard treatment to speed up recovery from mpox and reduce symptom duration.
What could go wrong: This is an extension study with no new treatment arm; results may not show clear benefit over placebo. The trial is completed but findings are not yet widely confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPOX (MONKEYPOX) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPOX (MONKEYPOX)

Contacts and locations

Locations

L'Hôpital Général de Référence de Kole

Kole, Democratic Republic of the Congo
L'Hôpital Général de Référence de Tunda

Tunda, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.